Tevogen Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | — | $11.1M | $31.0M | $4.4M | — |
| SG&A Expense | — | $15.0M | $22.5M | $4.4M | $953.1K |
| Operating Income | — | $-26.1M | $-53.6M | $-8.8M | — |
| Operating Margin | — | — | — | — | — |
| Interest Expense | — | — | $184.0K | $1.2M | — |
| Pretax Income | — | — | — | — | — |
| Income Tax Expense | — | $4.8K | $1.8K | — | — |
| Net Income | — | $-26.3M | $-13.7M | $-60.5M | $4.4M |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | — | $-8.08 | $-3.50 | $-2.44 | — |
| EPS (Diluted) | — | $-8.08 | $-3.50 | $-2.44 | — |
| Shares Outstanding (Basic) | 4.2M | 3.3M | 2.9M | 24.8M | 2.4M |
| Shares Outstanding (Diluted) | 4.2M | 3.3M | 2.9M | 24.8M | 2.4M |
| Dividends Per Share | — | — | — | — | — |